Nuvalent, Inc. Class A Common Stock
Symbol: NUVL (NASDAQ)
Company Description:
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
- Today's Open: $76.9
- Today's High: $82.045
- Today's Low: $74.74
- Today's Volume: 408.41K
- Yesterday Close: $76.8
- Yesterday High: $78.92
- Yesterday Low: $76.22
- Yesterday Volume: 250.81K
- Last Min Volume: 2
- Last Min High: $75.99
- Last Min Low: $75.99
- Last Min VWAP: $75.99
- Name: Nuvalent, Inc. Class A Common Stock
- Website: https://www.nuvalent.com
- Listed Date: 2021-07-29
- Location: CAMBRIDGE, MA
- Market Status: Active
- CIK Number: 0001861560
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $5.48B
- Round Lot: 100
- Outstanding Shares: 72.10M
- Asset Type: CS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-08 | 4 | View |
| 2025-08-07 | 10-Q | View |
| 2025-08-07 | 8-K | View |
| 2025-08-01 | 4 | View |
| 2025-07-24 | 144 | View |
| 2025-07-24 | 144 | View |
| 2025-07-24 | 144 | View |
| 2025-07-21 | 8-K | View |
| 2025-07-17 | SCHEDULE 13G | View |
| 2025-07-17 | 4 | View |
| 2025-07-17 | 4 | View |
| 2025-07-15 | 144 | View |
| 2025-07-11 | 4 | View |
| 2025-07-09 | 144 | View |
| 2025-07-01 | 4 | View |
| 2025-06-27 | 4 | View |
| 2025-06-27 | 4 | View |
| 2025-06-27 | 144 | View |
| 2025-06-26 | 144 | View |
| 2025-06-24 | 8-K | View |